RA Capital Nexus Fund II, L.P.
CIK 1825376
Transactions on file
26
Open-market buys
16
Win rate (buys)
50%
16 scored
Avg % since filing (buys)
+22.9%
Tickers traded
Recent activity
| Filed | Txn date | Issuer | Roles | Code | Shares | Value | % since Filing | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-13 | 2026-06-11 | JANX Janux Therapeutics, Inc. | Director | Grant | 5,500 | $0.00 | — | open → |
| 2026-06-05 | 2026-06-03 | ABOS Acumen Pharmaceuticals, Inc. | Director | Grant | 35,500 | $0.00 | — | open → |
| 2026-05-20 | 2026-05-18 | ACRV Acrivon Therapeutics, Inc. | Director | Grant | 9,366 | $0.00 | — | open → |
| 2026-04-23 | 2026-04-22 | ACRV Acrivon Therapeutics, Inc. | Director | Grant | 3,888,888 | $7.00M | -15.6% | open → |
| 2025-03-07 | 2025-03-05 | JANX Janux Therapeutics, Inc. | Director | Buy | 37,455 | $1.17M | -56.1% | open → |
| 2025-03-07 | 2025-03-05 | JANX Janux Therapeutics, Inc. | Director | Buy | 304,287 | $9.30M | -55.0% | open → |
| 2025-03-07 | 2025-03-07 | JANX Janux Therapeutics, Inc. | Director | Buy | 110,206 | $3.42M | -55.7% | open → |
| 2025-03-07 | 2025-03-06 | JANX Janux Therapeutics, Inc. | Director | Buy | 372,093 | $11.45M | -55.4% | open → |
| 2025-05-14 | 2025-05-12 | HOWL Werewolf Therapeutics, Inc. | Director10% | Buy | 320,913 | $276.0K | -54.8% | open → |
| 2025-05-14 | 2025-05-14 | HOWL Werewolf Therapeutics, Inc. | Director10% | Buy | 162,539 | $159.3K | -60.3% | open → |
| 2025-05-14 | 2025-05-13 | HOWL Werewolf Therapeutics, Inc. | Director10% | Buy | 52,974 | $51.9K | -60.3% | open → |
| 2025-06-05 | 2025-06-04 | ABOS Acumen Pharmaceuticals, Inc. | Director | Grant | 12,800 | $0.00 | — | open → |
| 2025-06-13 | 2025-06-11 | JANX Janux Therapeutics, Inc. | Director | Grant | 3,750 | $0.00 | — | open → |
| 2026-05-06 | 2026-05-06 | COAG Hemab Therapeutics Holdings, Inc. | Director | Buy | 53,407 | $1.33M | +1.0% | open → |
| 2026-05-06 | 2026-05-06 | COAG Hemab Therapeutics Holdings, Inc. | Director | Buy | 14,611 | $347.3K | +5.5% | open → |
| 2026-05-06 | 2026-05-05 | COAG Hemab Therapeutics Holdings, Inc. | Director | Buy | 10,268 | $256.7K | +0.3% | open → |
| 2026-05-06 | 2026-05-05 | COAG Hemab Therapeutics Holdings, Inc. | Director | Buy | 87,143 | $2.14M | +2.0% | open → |
| 2026-05-06 | 2026-05-04 | COAG Hemab Therapeutics Holdings, Inc. | Director | Buy | 133,750 | $2.41M | +39.3% | open → |
| 2026-05-06 | 2026-05-04 | COAG Hemab Therapeutics Holdings, Inc. | Director | Buy | 2,541,250 | $45.74M | +39.3% | open → |
| 2026-05-06 | 2026-05-04 | COAG Hemab Therapeutics Holdings, Inc. | Director | C | 221,188 | $0.00 | — | open → |
| 2026-05-06 | 2026-05-04 | COAG Hemab Therapeutics Holdings, Inc. | Director | C | 1,009,052 | $0.00 | — | open → |
| 2026-05-06 | 2026-05-04 | COAG Hemab Therapeutics Holdings, Inc. | Director | C | 3,607,846 | $0.00 | — | open → |
| 2025-12-15 | 2025-12-12 | CLYM Climb Bio, Inc. | Director | Buy | 101,462 | $290.2K | +301.7% | open → |
| 2025-12-15 | 2025-12-11 | CLYM Climb Bio, Inc. | Director | Buy | 213,099 | $464.6K | +427.1% | open → |
| 2025-12-15 | 2025-12-11 | CLYM Climb Bio, Inc. | Director | Disp. | 20,440,000 | $0.00 | — | open → |
| 2025-09-30 | 2025-09-26 | PEPG PepGen Inc. | Director | Buy | 9,375,000 | $30.00M | -52.2% | open → |
